Background/Aims: Transcatheter aortic valve implantation (TAVI) has emerged as a new therapeutic option for high-risk patients. However, dialysis patients were excluded from all previous studies. The aim of this study is to compare the outcomes of TAVI for dialysis patients with those for patients with chronic kidney disease (CKD) stages 3 and 4 and to compare TAVI with open surgery in dialysis patients. Methods: Part I: comparison of 10 patients on chronic hemodialysis with 116 patients with non-dialysis-dependent CKD undergoing TAVI. Part II: comparison of transcatheter (n = 15) with open surgical (n = 24) aortic valve replacement in dialysis patients. Results: Part I: dialysis patients were significantly younger (72.3 vs. 82.0 years; p < 0.01). Hospital stay was significantly longer in dialysis patients (21.8 vs. 12.1 days; p = 0.01). Overall 30-day mortality was 3.17%, with no deaths among dialysis patients. Six-month survival rates were similar (log-rank p = 0.935). Part II: patient age was comparable (66.5 vs. 69.5 years; p = 0.42). Patients in the surgical group tended to stay longer in hospital than TAVI patients (29.5 vs. 22.5 days; p = 0.35). Conclusion: TAVI is a safe procedure in patients on chronic hemodialysis. Until new data become available, we find no compelling reason to refuse these patients TAVI.

Keywords:
Surgical aortic valve replacement, Aortic stenosis, Transcatheter aortic valve implantation, Dialysis
1.
Baglin A, Hanslik T, Vaillant JN, Boulard JC, Moulonguet-Doleris L, Prinseau J: Severe valvular heart disease in patients on chronic dialysis. A five-year multicenter French survey. Ann Med Interne (Paris) 1997;148:521–526.
2.
Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996;27:394–401.
3.
Bryg RJ, Gordon PR, Migdal SD: Doppler-detected tricuspid, mitral or aortic regurgitation in end-stage renal disease. Am J Cardiol 1989;63:750–752.
4.
London GM, Pannier B, Marchais SJ, Guerin AP: Calcification of the aortic valve in the dialyzed patient. J Am Soc Nephrol 2000;11:778–783.
5.
Maher ER, Pazianas M, Curtis JR: Calcific aortic stenosis: a complication of chronic uraemia. Nephron 1987;47:119–122.
6.
Stinebaugh J, Lavie CJ, Milani RV, Cassidy MM, Figueroa JE: Doppler echocardiographic assessment of valvular heart disease in patients requiring hemodialysis for end-stage renal disease. South Med J 1995;88:65–71.
7.
Straumann E, Meyer B, Misteli M, Blumberg A, Jenzer HR: Aortic and mitral valve disease in patients with end stage renal failure on long-term haemodialysis. Br Heart J 1992;67:236–239.
8.
Urena P, Malergue MC, Goldfarb B, Prieur P, Guedon-Rapoud C, Petrover M: Evolutive aortic stenosis in hemodialysis patients: analysis of risk factors. Nephrologie 1999;20:217–225.
9.
Varma R, Aronow WS, McClung JA, Garrick R, Vistainer PF, Weiss MB, Belkin RN: Prevalence of valve calcium and association of valve calcium with coronary artery disease, atherosclerotic vascular disease, and all-cause mortality in 137 patients undergoing hemodialysis for chronic renal failure. Am J Cardiol 2005;95:742–743.
10.
Varadarajan P, Kapoor N, Bansal RC, Pai RG: Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg 2006;82:2111–2115.
11.
Edwards FH, Peterson ED, Coombs LP, DeLong ER, Jamieson WR, Shroyer ALW, Grover FL: Prediction of operative mortality after valve replacement surgery. J Am Coll Cardiol 2001;37:885–892.
12.
Iung B, Baron G, Butchart EG, et al: A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003;24:1231–1243.
13.
Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB: Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002;106:3006–3008.
14.
Leon MB, Smith CR, Mack M, et al: Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597–1607.
15.
Rodes-Cabau J, Webb JG, Cheung A, et al: Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol 2010;55:1080–1090.
16.
Lucke JC, Samy RN, Atkins BZ, Silvestry SC, Douglas JM Jr, Schwab SJ, Wolfe WG, Glower DD: Results of valve replacement with mechanical and biological prostheses in chronic renal dialysis patients. Ann Thorac Surg 1997;64:129–132, discussion 132–133.
17.
Tanaka K, Tajima K, Takami Y, Okada N, Terazawa S, Usui A, Ueda Y: Early and late outcomes of aortic valve replacement in dialysis patients. Ann Thorac Surg 2010;89:65–70.
18.
Herzog CA, Ma JZ, Collins AJ: Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified? Circulation 2002;105:1336–1341.
19.
Smith CR, Leon MB, Mack MJ, et al: Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187–2198.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.